ClinicalTrials.gg
CompletedNCT02249000BIOVALVEUpdated Jun 11, 2024

BIOVALVE - I / II Clincial Investigation

An interventional study of BIOVALVE prosthesis in Heart Valve Diseases and Aortic Valve Stenosis, sponsored by Biotronik AG. Completed at 13 sites in 4 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-06-11.

Primary conditionAortic Valve StenosisRegistry: Heart Valve DiseasesReclassifiedWhy we changed it
Registry
Heart Valve Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Aortic Valve Stenosis
Why
  1. The study's listed conditions name Aortic Valve Stenosis, a narrower term within Heart Valve Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Biotronik AG (formerly part of Biotronik SE & Co. KG) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.

Enrollment
72nd of 93
68 · median 220
Started
2014
with 12 others
No phase
82 of 191
13 open now
Registered
58th of 191
by date

Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 72nd largest by enrollment of the 93 interventional ones that give a count, is one of 13 that started in 2014, is one of 82 with no phase, and was the 58th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Aortic Valve Stenosis with a site in Germany, or all of them as a file.
02

Study summary

First-in-Human clinical investigation to evaluate the safety and clinical performance of the BIOVALVE prosthesis in subjects presenting with severe symptomatic aortic valve stenosis, which are as judged by the heart team, indicated for transfemoral transcatheter aortic valve implantation

Read the detailed description

In a non-randomized, prospective, multi-center clinical investigation, approximately 86 eligible subjects will be enrolled.

Phase 1: BIOVALVE-I feasibility clinical investigation: Approximately 13 eligible subjects will be enrolled.

Phase 2: BIOVALVE-II pilot clinical investigation: Approximately 73 eligible subjects will be enrolled.

BIOVALVE-I/II subjects follow the same clinical investigation plan (CIP) in all aspects.

03

Conditions studied

  • Heart Valve Diseases
  • Aortic Valve Stenosis

Browse trials for

04

In context

Aortic Valve Stenosis Reclassified

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

This study's enrollment of 68 is below the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.

Browse Aortic Valve Stenosis studies →

Lead sponsor

Biotronik AG is the lead sponsor of 40 studies on the registry; 2 are open to participants now.

First submitted before Biotronik AG left Biotronik SE & Co. KG.

Compared within Aortic Valve Stenosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Valve Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is ≥65 years
  2. The subject has provided written
  3. Subject is willing to participate in the clinical investigation and to comply with all of the study procedures and follow-up visits
  4. NHYA class ≥II
  5. High surgical risk: Logistic EuroSCORE-I ≥20% (or equivalence of EuroSCORE-II) or STS score ≥10% or co-morbidity judged by the heart team (consisting of at least one interventional cardiologist and one cardiac surgeon) to pose an absolute or relative for conventional aortic valve replacement according to VARC-2
  6. Severe symptomatic calcific aortic valve stenosis characterized by mean aortic gradient >40 mm Hg or peak jet velocity >4.0 m/s or effective orifice area (EOA) of \<1.0 cm2 (\<0.6 cm2/m2 body surface area)
  7. Annulus diameter as determined by multi-slice computed tomography (MSCT) from 23-26 mm

Exclusion criteria

Exclusion Criteria:

  1. Trans-esophageal echocardiogram (TEE) is
  2. Congenital bicuspid or unicuspid valve
  3. Left ventricular outflow tract (LVOT) obstruction such as hypertrophic obstructive cardio myopathy (HOCM) or subject presenting with systolic anterior motion (SAM). Evidence of intra cardiac mass, thrombus or vegetation
  4. Transfemoral access vessel characteristics that would preclude safe placement of a 18 French sheath
  5. Vessel and/or anatomical characteristics that would preclude safe delivery of the BIOVALVE prosthesis to the ascending aorta and/or placement of the prosthesis
  6. Anatomical restrictions such as shallow sinuses with heavily calcified leaflets, low height of coronary ostia, extreme tortuosity of the aortic arch, thoracic (TAA) or abdominal (AAA) aortic aneurysm, presence of endovascular stent graft
  7. Severe mitral regurgitation grade >3
  8. Severe mitral stenosis
  9. Prosthetic mitral valve
  10. Severe left ventricular dysfunction with (LVEF) \<20%
  11. Hemodynamic instability
  12. Percutaneous coronary intervention (PCI) within 30 days prior to index procedure and / or planned PCI during index procedure
  13. Renal insufficiency (creatinine >2.5 mg/dl) or subject under dialysis and/or renal replacement therapy
  14. Any cerebrovascular event or (TIA) within 180 days prior to TAVI procedure
  15. Evidence of acute myocardial infarction (defined as ≥2 fold CK level or in absence of CK a ≥3 fold CKMB level above the upper range limit within ≤30 days prior to TAVI procedure)
  16. Blood dyscrasia defined as: leucopenia (WBC \<1000 mm³), thrombocytopenia ( count \<50'000 cells/mm³), history of bleeding diathesis requiring blood transfusion
  17. Ongoing sepsis or suspected active endocarditis
  18. Active peptic ulcer or gastrointestinal bleeding within last 3 months that would preclude anticoagulation
  19. Subject refuses blood transfusion
  20. Known to, or contraindication to nitinol, anticoagulation/antiplatelet regimes, any other medications required for the procedure or post-procedure as determined by the heart team, or sensitivity to contrast media which cannot be adequately pre-medicated
  21. Need for emergency TAVI intervention, or other medical, social, or psychological conditions that in the opinion of the heart team precludes the subjects from appropriate consent or adherence to protocol required follow-up exams
  22. Expectation that subject will not improve despite treatment of aortic stenosis
  23. Estimated of less than 12 months due to associated non-cardiac co-morbidities
  24. Severe pulmonary hypertension (> 60 mm Hg assessed by continuous wave Doppler, TTE) or clinical signs of acute severe right ventricular dysfunction
  25. Currently participating in another drug or device study where primary endpoint has not been reached yet
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    BIOVALVE prosthesis

    Transcatheter Aortic Valve Replacement (TAVR)

    Device: BIOVALVE prosthesis

Interventions

  • DeviceBIOVALVE prosthesis

    Transcatheter Aortic Valve Replacement (TAVR)

07

What researchers measure

Primary outcomes

  1. Early safety at 30 days (Acc. to VARC-2)

    A composite of all-cause mortality, all stroke (disabling/non-disabling), life-threatening bleeding, acute kidney injury stage 2 or 3 (including renal replacement therapy), coronary artery obstruction requiring intervention, major vascular complication and valve-related dysfunction requiring repeat procedure (balloon aortic valvuloplasty (BAV), transcatheter aortic valve implantation (TAVI), or surgical aortic valve replacement (SAVR)).

    Time frame: 30 days

Secondary outcomes

  1. Combined safety endpoint at 30 days (Acc. to VARC-1)

    A composite of all-cause mortality, major stroke, life-threatening (or disabling) bleeding, acute kidney injury stage 3 (including renal replacement therapy), peri-procedural myocardial infarction, major vascular complication and repeat procedure for valve-related dysfunction (surgical or interventional therapy)

    Time frame: 30 days

  2. Clinical efficacy after 30 days (Acc. to VARC-2):

    A composite of all-cause mortality, all stroke (disabling and non-disabling), requiring hospitalizations for valve-related symptoms or worsening congestive heart failure, NYHA class III or IV, valve-related dysfunction (mean aortic valve gradient ≥20 mm Hg, effective orifice area (EOA) ≤0.9-1.1 cm2 \* and/or Doppler velocity index (DVI) \<0.35 m/s, and/or moderate or severe prosthetic valve regurgitation \*\*). \* depending on body surface area \*\* refers to VARC-2 definitions

    Time frame: 30 days

  3. Echocardiograhic (ECHO) parameters

    Effective orifice area (EOA) and effective orifice area index (EOAI) Mean prosthetic valve gradient Prosthetic valve regurgitation (Acc. to VARC-1 and VARC-2)

    Time frame: Discharge, 30 days, 6 months, 12 months and annually through 5 years

08

Study locations

13 sites
  • ZNA Middelheim
    Antwerpen, 2020, Belgium
  • Städtische Kliniken Neuss - Lukaskrankenhaus
    Neuss, Nordrhein-Westfalen 41464, Germany
  • Segeberger Kliniken
    Bad Segeberg, Schleswig-Holstein 23795, Germany
  • Vivantes Klinikum
    Berlin, 10249, Germany
  • German Heart Center
    Berlin, 13353, Germany
  • Universitätsklinikum Halle (Saale)
    Halle, 06120, Germany
  • Asklepios Klinik St. Georg
    Hamburg, 20099, Germany
  • University Heart Center
    Hamburg, 20246, Germany
  • University Heart Center
    Köln, 50937, Germany
  • Herzzentrum Leipzig
    Leipzig, 04289, Germany
  • Universitätsmedizin Rostock
    Rostock, 18057, Germany
  • Catharina-Ziekenhuis
    Eindhoven, 5623, Netherlands
  • Universitätsspital Zürich
    Zurich, 8091, Switzerland
09

References and documents

Publications

  • Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodes-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB; Valve Academic Research Consortium-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. EuroIntervention. 2012 Nov 22;8(7):782-95. doi: 10.4244/EIJV8I7A121. PubMed 23022744 ↗
  • Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, Mehran R, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol. 2011 Jan 18;57(3):253-69. doi: 10.1016/j.jacc.2010.12.005. Epub 2011 Jan 7. PubMed 21216553 ↗
  • Treede H, Lubos E, Conradi L, Deuschl F, Asch FM, Weissman NJ, Schofer N, Schirmer J, Koschyk D, Blankenberg S, Reichenspurner H, Schaefer U. Thirty-day VARC-2 and performance data of a new self-expanding transcatheter aortic heart valve. EuroIntervention. 2015 Nov;11(7):785-92. doi: 10.4244/EIJY15M05_05. PubMed 25983028 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Mar 2018 and a completion of May 2023. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2014
First posted
Sep 25, 2014
Start
Sep 2014
Primary completionActual
Mar 2018
CompletionActual
May 2023
Last update
Jun 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02249000
Lead sponsor
Biotronik AG
Responsible party
Sponsor
First posted
Sep 25, 2014
Start date
Sep 2014
Primary completion
Mar 2018
Completion
May 2023
Last update
Jun 11, 2024

Study contacts

Hendrik Treede, MD
study chair · Universitätsklinikum Halle (Saale), Germany
Ulrich Schaefer, MD
study chair · University Heart Center Hamburg, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion